3-Oxo-hexahydro-1H-isoindole-4-carboxylic Acid as a Drug Chiral Bicyclic Scaffold: Structure-Based Design and Preparation of Conformationally Constrained Covalent and Noncovalent Prolyl Oligopeptidase Inhibitors.
暂无分享,去创建一个
Nicolas Moitessier | A. Mittermaier | Stephane De Cesco | N. Moitessier | K. Auclair | Gaëlle Mariaule | Stéphane De Cesco | Francesco Airaghi | Jerry Kurian | Paolo Schiavini | Sylvain Rocheleau | Igor Huskić | Karine Auclair | Anthony Mittermaier | I. Huskić | Paolo Schiavini | Jerry Kurian | S. Rocheleau | F. Airaghi | Gaëlle Mariaule
[1] A. Stepan,et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. , 2011, Chemical research in toxicology.
[2] N. Moitessier,et al. Solvent effect in diastereoselective intramolecular Diels–Alder reactions , 2015 .
[3] Z. Zuo,et al. Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions , 2012, Expert opinion on drug metabolism & toxicology.
[4] Louis J. Farrugia,et al. WinGX suite for small-molecule single-crystal crystallography , 1999 .
[5] Christopher R. Corbeil,et al. Docking Ligands into Flexible and Solvated Macromolecules, 1. Development and Validation of FITTED 1.0 , 2007, J. Chem. Inf. Model..
[6] Wei Duan,et al. Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance , 2005, Drug metabolism reviews.
[7] Nathanael Weill,et al. Docking Ligands into Flexible and Solvated Macromolecules, 7. Impact of Protein Flexibility and Water Molecules on Docking-Based Virtual Screening Accuracy , 2014, J. Chem. Inf. Model..
[8] P. V. von Hippel,et al. Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.
[9] G. Sheldrick. A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.
[10] J. G. Robertson,et al. Mechanistic basis of enzyme-targeted drugs. , 2005, Biochemistry.
[11] C. Pham-Huy,et al. Chiral Drugs: An Overview , 2006, International journal of biomedical science : IJBS.
[12] Nicolas Moitessier,et al. Constrained peptidomimetics reveal detailed geometric requirements of covalent prolyl oligopeptidase inhibitors. , 2009, Journal of medicinal chemistry.
[13] Tanya Singh,et al. AADS - An Automated Active Site Identification, Docking, and Scoring Protocol for Protein Targets Based on Physicochemical Descriptors , 2011, J. Chem. Inf. Model..
[14] Erik A. A. Wallén,et al. Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. , 2006, Biochemical pharmacology.
[15] N. Moitessier,et al. Metabolic Instability of Cyanothiazolidine‐Based Prolyl Oligopeptidase Inhibitors: a Structural Assignment Challenge and Potential Medicinal Chemistry Implications , 2015, ChemMedChem.
[16] B. O'connor,et al. Identification and Initial Characterization of a N-Benzyloxycarbonyl-Prolyl-Prolinal (Z-Pro-Prolinal)-Insensitive 7-(N-Benzyloxycarbonyl-Glycyl-Prolyl-Amido)-4-Methylcoumarin (Z-Gly-Pro-NH-Mec)-Hydrolysing Peptidase in Bovine Serum , 1997 .
[17] M. Potashman,et al. Covalent modifiers: an orthogonal approach to drug design. , 2009, Journal of medicinal chemistry.
[18] A. Kalgutkar,et al. Drug discovery for a new generation of covalent drugs , 2012, Expert opinion on drug discovery.
[19] L. Guterman,et al. COVALENT DRUGS FORM LONG-LIVED TIES: IRREVERSIBLE INHIBITORS may provide unique benefits in drug development , 2011 .
[20] J F Morrison,et al. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. , 1969, Biochimica et biophysica acta.
[21] V. Fülöp,et al. Electrostatic Effects and Binding Determinants in the Catalysis of Prolyl Oligopeptidase , 2002, The Journal of Biological Chemistry.
[22] Adrian Whitty,et al. The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.
[23] J. Mascareñas,et al. Palladium-catalyzed [4+3] intramolecular cycloaddition of alkylidenecyclopropanes and dienes. , 2007, Journal of the American Chemical Society.
[24] A. Lambeir. Translational research on prolyl oligopeptidase inhibitors: the long road ahead , 2011, Expert opinion on therapeutic patents.
[25] T. Tarragó,et al. Low molecular weight inhibitors of Prolyl Oligopeptidase: a review of compounds patented from 2003 to 2010 , 2011, Expert opinion on therapeutic patents.
[26] K N Houk,et al. Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. , 2009, Journal of medicinal chemistry.
[27] J. Hakkarainen,et al. Brain pharmacokinetics of two prolyl oligopeptidase inhibitors, JTP-4819 and KYP-2047, in the rat. , 2011, Basic & clinical pharmacology & toxicology.
[28] V. Fülöp,et al. P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy. , 2012, Journal of medicinal chemistry.
[29] V. Fülöp,et al. Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide. , 2010, Bioorganic & medicinal chemistry.
[30] Nicolas Moitessier,et al. Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells. , 2012, Journal of medicinal chemistry.
[31] B. Cravatt,et al. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. , 2010, Future medicinal chemistry.
[32] Valérie Campagna-Slater,et al. Integrating Medicinal Chemistry, Organic/Combinatorial Chemistry, and Computational Chemistry for the Discovery of Selective Estrogen Receptor Modulators with Forecaster, a Novel Platform for Drug Discovery , 2012, J. Chem. Inf. Model..
[33] V. Baekelandt,et al. A prolyl oligopeptidase inhibitor, KYP‐2047, reduces α‐synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease , 2012, British journal of pharmacology.
[34] J. Tenorio-Laranga,et al. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson’s and Alzheimer’s diseases , 2013, Neuroscience.
[35] L. Juillerat-Jeanneret,et al. Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. , 2010, Journal of medicinal chemistry.
[36] Ernesto Callegari,et al. A comprehensive listing of bioactivation pathways of organic functional groups. , 2005, Current drug metabolism.
[37] F. Fleming,et al. Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. , 2010, Journal of medicinal chemistry.
[38] A. Lambeir. Interaction of prolyl oligopeptidase with α-synuclein. , 2011, CNS & neurological disorders drug targets.
[39] F. Checler,et al. S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. , 1999, Biochemical and biophysical research communications.
[40] Y. Iwamoto,et al. A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease , 1997, Behavioural Brain Research.